Overview of the Ozempic Litigation
The federal judge overseeing the Ozempic litigation, Hon. Gene E.K. Pratter, conducted the first status conference on March 14, 2024, addressing the ongoing weight loss and diabetes drug mass tort litigation. This significant legal event took place in the United States District Court for the Eastern District of Pennsylvania.
Current Status of the Ozempic Litigation
As of the conference date, the litigation comprised approximately 55 individual lawsuits. Notably, the majority of these cases, around 54, were claims against Ozempic, with one against another manufacturer.
The cases predominantly involved “on-label” usage, where Ozempic was prescribed to treat type 2 diabetes, with about 10% prescribed off-label for weight loss.
Ozempic Legal Claims and Issues Discussed
The litigation encompasses various claims, including failure to warn of Ozempic injuries, issues related to the drug’s design, and violations of state consumer protection laws.
Judge Pratter discussed the possibility of establishing separate tracks for the litigation to manage these diverse issues effectively.
Organizational Structure and Expectations
The court also focused on the organization of Ozempic plaintiff lawyers, outlining expectations for the composition of various committees. Judge Pratter emphasized the need for the litigation to progress swiftly, in line with section 21.272 of the Manual for Complex Litigation.
Litigation Procedures and Protocols
Ongoing and Future Litigation Activities
Negotiations are underway to establish a schedule for motion practice. The court plans to hold monthly status conferences to ensure the litigation’s steady advancement. Out-of-state attorneys have the option to participate in the litigation by filing pro hac vice motions through Pennsylvania attorneys, like those at The Levensten Law Firm.
Docket Information
The main docket for this litigation is numbered 2:24-md-03094-GEKP, serving as the central reference for all related legal proceedings and documents.
